FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1398-1399 September 25, 2008 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Rossebø, A. B. Related Article by Peto, R. PubMed Citation

The randomized clinical trial is considered to be the most reliable tool to assess the efficacy and safety of new drugs. At times, however, randomized trials detect adverse events that are unanticipated and not easily explained on the basis of current knowledge. An unexpected finding of this kind may ultimately prove to be due to chance, but follow-up studies sometimes confirm the adverse drug effect. Particularly when an unexpected finding raises a safety concern with regard to a drug, physicians face uncertainty about how to act on the information.

In this issue of the Journal, we publish the results of . . . [Full Text of this Article]

Source Information

This article (10.1056/NEJMe0807200) was published at www.nejm.org on September 2, 2008.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.